Skip to content
DataLookout
Menu

NCT06733610

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With AIHA Who Have Failed ≥3 Lines of Therapy.

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Feb 5, 2026 to Jan 12, 2027 Show 7 more changesShow less
    • Eligibility criteria expanded, about 24 words
    • Enrollment closed, study ongoing
    • Final enrollment: 5 participants (planned 15)
    • Study completion pushed from Dec 5, 2026 to Dec 31, 2027
    • Interventions: universal allogeneic anti-CD19/BCMA CAR T-cells (Biological) to universal allogeneic anti-CD19/BCMA CAR T-cells (Biological)
    • Site details revised
    • Collaborators: details revised at 1 of 1 entry
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

The number and severity of dose-limiting toxicity (DLT) events
Timeframe: Within 28 Days After UCAR T-cell Infusion
The total number, incidence, and severity of AEs
Timeframe: Up to 12 Months After UCAR T-cell Infusion
Clinical response of AIHA who have failed ≥ 3 lines of therapy
Timeframe: Up to 24 Weeks After UCAR T-cell Infusion

Arms and interventions

UCAR T-cell groupExperimental

Universal allogeneic anti-CD19/BCMA CAR T-cells.

Biologicals: universal allogeneic anti-CD19/BCMA CAR T-cells

Sites

1 site in 1 country

  • Regenerative Medicine Center and Red Blood Cell Disorders CenterTianjin, Tianjin Municipality, China